With Takeda out of the picture, J&J’s Rybrevant moves into first line in lung cancer subtype

04 Mar 2024
www.fiercepharma.com
Phase 3Drug ApprovalClinical ResultPriority Review
With Takeda out of the picture, J&J’s Rybrevant moves into first line in lung cancer subtype
Preview
Source: FiercePharma
Johnson & Johnson believes its lung cancer regimen of Rybrevant and lazertinib could together reach more than $5 billion in peak sales.
Johnson & Johnson continues to grow its oncology franchise with a new FDA approval that opens the lung cancer drug Rybrevant to treating certain newly diagnosed patients.
Friday’s approval allows Rybrevant to be used alongside the chemotherapies carboplatin and pemetrexed as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.
Simultaneously, Rybrevant’s original accelerated approval as a single agent for chemo-pretreated tumors has been converted to a full approval, the agency said.
Rybrevant’s first-line nod comes five months after Takeda announced a voluntary market withdrawal of its rival EGFR exon 20 NSCLC drug, Exkivity, which failed as a monotherapy in its own first-line trial. Before their divergent phase 3 reports, the two drugs were sharing the second-line market roughly 50-50.
The FDA considered positive data from the phase 3 PAPILLON trial in granting Rybrevant the first-line indication. Compared with chemo alone, the combination of Rybrevant and chemo cut the risk of progression or death by 60% in patients with NSCLC with EGFR exon 20 insertion mutations. Patients who received the J&J bispecific went 11.4 months without their disease worsening, compared with 6.7 months for those in the control arm.
While patient survival data remained immature—with only 44% of deaths required for the final overall survival analysis—“no trend towards a detriment was observed,” the FDA noted in Rybrevant’s new label.
Previously, with 33% data maturity, the Rybrevant-chemo regimen showed a trend toward a 33% reduction in the risk of death. Nearly half of patients in the chemo-alone arm later went on to receive single-agent Rybrevant following disease progression.
Although Takeda’s Exkivity is out of the picture, other small-molecule agents targeting EGFR exon 20 NSCLC are biding their time to challenge J&J’s antibody drug.
ArriVent BioPharma, which recently staged an upsized IPO, is working on a pan-EGFR mutant inhibitor called furmonertinib. The drug, licensed to ArriVent by Allist Pharma, was approved in China originally for second-line treatment of NSCLC with certain EGFR mutations; it moved into the first line in 2022. Following a similar development strategy as Takeda’s approach, Arrivent is currently running the phase 3 FURVENT trial testing furmonertinib monotherapy against chemo in previously untreated NSCLC with EGFR exon 20 insertion mutations.
Meanwhile, AstraZeneca spinout Dizal Pharmaceutical is also looking to bring its China-approved sunvozertinib to EGFR exon 20 NSCLC in the U.S. market. Dizal also has a phase 3 trial evaluating the drug by itself against chemo in the first-line setting, and the company recently told Fierce Biotech that it was talking to Big Pharma companies about a potential partnership.
EGFR exon 20 mutations only represent a small market, with an estimated frequency of about 0.1% to 4% of all NSCLC cases.
For Rybrevant, the most important indication would be first-line NSCLC with the more prevalent exon 19 or exon 21 abnormalities, where AstraZeneca’s blockbuster Tagrisso is king. There, J&J recently earned FDA priority review for its application of Rybrevant and its Yuhan-partnered lazertinib based on a head-to-head win against Tagrisso in the phase 3 MARIPOSA trial.
If approved, the Rybrevant-lazertinib regimen would need to challenge both Tagrisso monotherapy and a Tagrisso-chemo combination.
During a recent investor event, J&J laid out an ambition to snag about half of first-line patients in EGFR-mutant NSCLC. J&J believes the Rybrevant-lazertinib regimen could reach over $5 billion in peak sales. In 2023, AZ’s Tagrisso generated $5.9 billion in sales, good for 9% growth at constant exchange rates.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.